Healthcare 21 Group has received approval from the Competition and Consumer Protection Commission to allow for the completion of the purchase of Aquilant Limited from H2 Equity Partners.
Healthcare 21, the Cork-based specialist supplier of innovative healthcare solutions, is enjoying an exciting new growth phase. The newly combined business employs more than 450 staff in Ireland, UK, Germany and Austria and has turnover in excess of €150m. This latest acquisition follows the significant expansion of the Healthcare 21 group that in two years has more than doubled in size.
As part of the acquisition, H2 Equity Partners will become a substantial minority shareholder in the newly enlarged Healthcare 21 Group, which will focus on investing in Europe to drive future growth. The combination of HC21 and Aquilant will create a new market-leading group of specialist medical sales teams with an in-depth knowledge and understanding of the healthcare market. Healthcare 21 Group has enjoyed significant expansion in recent years and will continue to be led by founding directors Owen Curtin, Tara Kearney and David Frederick.
Healthcare 21 Group Chairman Owen Curtin said: “The combination of Aquilant and HC21 represents a fabulous opportunity. The scale of our now expanded Healthcare 21 Group and the experience and talent of our people will ensure significant growth and success for all involved. I look forward to us realising this potential together.
“Aquilant is an ideal addition to the Healthcare 21 Group and offers an expanded product portfolio in many exciting therapy areas that Healthcare 21 previously did not serve including cardiothoracic, spinal, orthopaedic and neurosurgical specialties. In addition, the Aquilant business infrastructure with a substantial UK presence will ensure that both companies can maintain focus on their current plans and continue to deliver world class outcomes for our customers.”
The Healthcare 21 group is focused on increasing its portfolio scope within its existing partners as well as continuing to look for new partners as and acquisition opportunities as it targets further European expansion.